Wire · opportunities
FDA clears blood test to aid evaluation for Alzheimer's disease
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 23 August 2026 · Fusion42 review
The FDA has cleared PrecivityAD2, a blood-based test developed by C2N Diagnostics and Washington University, to aid in identifying brain amyloid plaques associated with Alzheimer's disease. This test offers a less invasive diagnostic method compared to cerebrospinal fluid testing and supports earlier treatment of Alzheimer’s disease.
This Wire brief sits within Fusion42's coverage of Digital Health, and 9 sources have reported it between 20 Aug 2026 and 22 Aug 2026.
◆ ◆ The Wire takeaway
You face a new way to diagnose Alzheimer’s with less invasive testing that can hasten patient treatment starts. Clinicians and health systems now have FDA-backed tools that could shift how you market and position diagnostics for cognitive decline.
◆ Coverage
9 sources · first reported 20 Aug 2026 · latest 22 Aug 2026
◆ Related on Wire
◆ Topics